TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3720387

Group type: EXPERIMENTAL
Intervention: Intrathoracic intercostal nerve block using phenol
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no nerve block)
Number of subjects: 73
Study: 30789575

Group type: EXPERIMENTAL
Intervention: Supplementary strength training program (twice per week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CON) performing 8 weeks of fencing training (4 times per week) without supplementary strength training
Number of subjects: 20
Study: 31227373

Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionation (42·7 Gy in seven fractions, 3 days per week for 2·5 weeks)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Conventional fractionation (78·0 Gy in 39 fractions, 5 days per week for 8 weeks)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionation
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 1200
Study: 29145540

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 26141155

Group type: EXPERIMENTAL
Intervention: 21-session after-school SRH programme
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: School health services
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Participants with sexual debut before baseline
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Participants who had been victims of sexual violence or intimate partner violence (IPV)
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Participants motivated by a wish to receive new knowledge, life coaching and positive attitudes towards the intervention
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Unavailability of safe transport and domestic responsibilities
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Negative attitudes about the intervention
Number of subjects: 1576
Study: 23322502

Group type: EXPERIMENTAL
Intervention: Wii group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 22027191

Group type: EXPERIMENTAL
Intervention: Immunonutrition (IM) group: 750 ml of IMPACT plus half‐size hospital meals orally from 5 days before to the day before surgery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (C) group: Conventional hospital meals
Number of subjects: 26
Study: 18298219

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing varnish
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brackets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bands
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no varnish)
Number of subjects: 40
Study: 17211119

Group type: EXPERIMENTAL
Intervention: PMS nutritional education program for 8 weeks
Number of subjects: 56
Study: 14627214

Group type: EXPERIMENTAL
Intervention: Experimental Tampax tampon
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control Tampax tampon
Number of subjects: 110
Study: 11210392

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (OTC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9248049

Group type: EXPERIMENTAL
Intervention: Communication about highly overlapping information
Number of subjects: 432

Group type: COMPARATOR
Intervention: No communication with nonoverlapping information
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Communication, overlap, and target consistency
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Communication and stimulus overlap
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Perceiver communication
Number of subjects: 432
Study: 8391282

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colistin 1 million IU
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3103163

Group type: EXPERIMENTAL
Intervention: Aniracetam 1 g daily for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31778599

Group type: EXPERIMENTAL
Intervention: CYP2C19∗2 allele (homozygote or mutation heterozygote)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: ABCB1 (C3435C>T) polymorphism
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Total incidence of allelic disorders of low drug absorption and metabolism
Number of subjects: 199
Study: 28779961

Group type: EXPERIMENTAL
Intervention: Swaddling during heel lance
Number of subjects: 74

Group type: COMPARATOR
Intervention: Routine heel lance (control)
Number of subjects: 74
Study: 26867336

Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric bupivacaine 8.121 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric bupivacaine 9.012 mg
Number of subjects: 84
Study: 23170788

Group type: EXPERIMENTAL
Intervention: Cervical exams plus fetal fibronectin (FFN)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cervical exams only (Control)
Number of subjects: 76
Study: 21044870

Group type: EXPERIMENTAL
Intervention: GAD-alum treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18727138

Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cystectomy (RARC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 30
Study: 16569804

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study: 14522153

Group type: EXPERIMENTAL
Intervention: Screening for colorectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-treatment life expectancy and survival in females from more-deprived areas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Socio-economic deprivation
Number of subjects: 0
Study: 11120456

Group type: EXPERIMENTAL
Intervention: Behavior-modifying education
Number of subjects: 49
Study: 8855394

Group type: EXPERIMENTAL
Intervention: intensive group (ultrasound imaging and continuous wave Doppler studies at 18, 24, 28, 34 and 38 weeks gestation)
Number of subjects: 2743

Group type: EXPERIMENTAL
Intervention: intensive group
Number of subjects: 2743

Group type: COMPARATOR
Intervention: regular group (single imaging examination at 18 weeks and further imaging scans only as clinically indicated)
Number of subjects: 2743
Study: 1815001

Group type: EXPERIMENTAL
Intervention: Readables
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single vision reading lens (Control)
Number of subjects: 0
Study: 6668565

Group type: EXPERIMENTAL
Intervention: Provision of sensation information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived control and distraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine dentistry
Number of subjects: 0
Study: 31056681

Group type: EXPERIMENTAL
Intervention: Caffeine (median 1.6 mg/L for dipyridamole; 7.4 mg/L for regadenoson)
Number of subjects: 6087

Group type: COMPARATOR
Intervention: No caffeine (control)
Number of subjects: 6087

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 6087
Study: 28525981

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally 1 hour before anesthesia and Ramosetron 0.3 mg intravenously at the end of surgery (Group GR)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Gabapentin 300 mg orally 1 hour before anesthesia (Group G)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Ramosetron 0.3 mg intravenously at the end of surgery (Group R)
Number of subjects: 132
Study: 26375824

Group type: EXPERIMENTAL
Intervention: Opioid therapy (morphine equivalents)
Number of subjects: 81
Study: 23417581

Group type: EXPERIMENTAL
Intervention: LA-IP approach
Number of subjects: 108

Group type: COMPARATOR
Intervention: SA-OOP approach
Number of subjects: 108
Study: 20464539

Group type: EXPERIMENTAL
Intervention: Vitamin C and E (VCE) administration before anesthesia with desflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with desflurane anesthesia without VCE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin C and E (VCE) administration
Number of subjects: 40
Study: 19816079

Group type: EXPERIMENTAL
Intervention: XM02
Number of subjects: 608

Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 608
Study: 17404193

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 15202986

Group type: EXPERIMENTAL
Intervention: Telephone-delivered message emphasizing personal responsibility
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Telephone-delivered message emphasizing social responsibility
Number of subjects: 528
Study: 11518436

Group type: EXPERIMENTAL
Intervention: Instrumental Enrichment (dynamic cognitive treatment)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Traditional occupational therapy methods (control group)
Number of subjects: 58
Study: 9844792

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg/70 kg bolus and 3.5 mg/70 kg/hour for 4 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Morphine and M-6-G combination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: M-6-G (doses producing plasma concentrations identical, 2x, or 3x higher than morphine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8822914

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at an initial dosage of 20 mg/kg/d for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 25
Study: 2184135

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus poly(A).poly(U)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 224
Study: 6788319

Group type: EXPERIMENTAL
Intervention: Diazepam (25 mg daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Promethazine (125 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30556414

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray plus twice‐daily phone call reminders
Number of subjects: 24

Group type: COMPARATOR
Intervention: Desoximetasone 0.25% spray
Number of subjects: 24
Study: 28576629

Group type: EXPERIMENTAL
Intervention: Robotic resistance treadmill training (n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Robotic assistance treadmill training (n=11)
Number of subjects: 23
Study: 27852718

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) consisting of 10 high-intensity (85-90% peak power output) and 10 low-intensity (20-25% peak power output) intervals, each lasting 1 minute, for 8 weeks, twice weekly.
Number of subjects: 510

Group type: COMPARATOR
Intervention: Moderate-intensity steady-state training (MISS) following usual care recommendations, adhering to UK guidelines (>20 minutes continuous exercise at 40-70% heart rate reserve), for 8 weeks, twice weekly.
Number of subjects: 510
Study: 24628999

Group type: COMPARATOR
Intervention: Conventional corneal crosslinking (CXL; n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corneal crosslinking with mechanical compression (CRXL; n = 30)
Number of subjects: 60
Study: 22541945

Group type: EXPERIMENTAL
Intervention: Variable-stiffness shoe
Number of subjects: 11

Group type: COMPARATOR
Intervention: Constant-stiffness control shoe
Number of subjects: 11
Study: 20424418

Group type: EXPERIMENTAL
Intervention: 0.7 mg/m2/day biosynthetic GH
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1.4 mg/m2/day biosynthetic GH
Number of subjects: 35
Study: 17911178

Group type: EXPERIMENTAL
Intervention: 20 microg TPTD
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: 40 microg TPTD
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study: 15730354

Group type: EXPERIMENTAL
Intervention: Various medications (specific medications not detailed)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 11874742

Group type: EXPERIMENTAL
Intervention: CAT‐152 (100 microg in 100 microl)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CAT‐152
Number of subjects: 24
Study: 9043535

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 7 mg over 8 hours via metered-dose inhaler (MDI) attached to a holding chamber
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered in the same fashion as BDP
Number of subjects: 60
Study: 7957146

Group type: EXPERIMENTAL
Intervention: 1800 kcal.24 h‐1 (7560 kJ, LC)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 3200 kcal.24 h‐1 (13440 kJ, MC)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 4200 kcal.24 h‐1 (17,640 kJ, HC)
Number of subjects: 27
Study: 2438966

Group type: EXPERIMENTAL
Intervention: Antihistamine/decongestant
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29787355

Group type: EXPERIMENTAL
Intervention: Lavender cream and footbath
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Lavender cream alone
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 141
Study: 27534742

Group type: EXPERIMENTAL
Intervention: School and household intervention combining dietary changes and increased physical activity
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2500
Study: 24627349

Group type: EXPERIMENTAL
Intervention: Baseline systolic BP increase by 20 mmHg
Number of subjects: 3474

Group type: EXPERIMENTAL
Intervention: Diastolic BP levels <70 mmHg with a decrease of 10 mmHg
Number of subjects: 3474

Group type: EXPERIMENTAL
Intervention: Diastolic BP levels >70 mmHg
Number of subjects: 3474
Study: 22435598

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20335158

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) and azithromycin (10 mg/kg daily, intravenously)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Azithromycin (10 mg/kg daily, intravenously)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined treatments (TCM and WM)
Number of subjects: 90
Study: 18709590

Group type: EXPERIMENTAL
Intervention: School-based educational intervention on health genealogy workshops
Number of subjects: 6

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 6
Study: 15780168

Group type: EXPERIMENTAL
Intervention: Low dose rate brachytherapy monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy options
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matched analyses with uniform patient treatment and pathological review
Number of subjects: 0
Study: 12091849

Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine/zidovudine
Number of subjects: 23

Group type: COMPARATOR
Intervention: lamivudine/zidovudine
Number of subjects: 23
Study: 10347106

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 225
Study: 8613013

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg/kg/day)
Number of subjects: 26
Study: 1888818

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine nocte
Number of subjects: 208

Group type: COMPARATOR
Intervention: 150 mg ranitidine nocte
Number of subjects: 208
Study: 6401807

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (40 to 400 micrograms/kg/day)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Copper supplementation (20 or 40 micrograms/kg/day)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Zinc and copper supplementation
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Reference ranges for serum zinc, copper, retinol‐binding protein, prealbumin, and ceruloplasmin
Number of subjects: 127
Study: 31138522

Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU/week
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 30080254

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol self-administration after 2 weeks of abstinence
Number of subjects: 50
Study: 27997653

Group type: EXPERIMENTAL
Intervention: Pritelivir 100 mg daily for 28 days
Number of subjects: 91

Group type: COMPARATOR
Intervention: Valacyclovir 500 mg daily for 28 days
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pritelivir
Number of subjects: 91

Group type: COMPARATOR
Intervention: Valacyclovir
Number of subjects: 91
Study: 24488184

Group type: EXPERIMENTAL
Intervention: Direct-to-consumer advertising (DTCA) about Cymbalta (an antidepressant)
Number of subjects: 272
Study: 22281110

Group type: EXPERIMENTAL
Intervention: PPI and rebamipide combination therapy
Number of subjects: 290

Group type: COMPARATOR
Intervention: PPI alone
Number of subjects: 290
Study: 20418698

Group type: EXPERIMENTAL
Intervention: SSI-guided analgesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 17425830

Group type: EXPERIMENTAL
Intervention: Wallace catheter
Number of subjects: 260

Group type: COMPARATOR
Intervention: Labotect catheter
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Wallace catheter (as treated)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Labotect catheter (as treated)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Wallace catheter (catheter change due to unsuccessful negotiation)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Labotect catheter (catheter change due to unsuccessful negotiation)
Number of subjects: 260
Study: 16390780

Group type: EXPERIMENTAL
Intervention: Estrogen replacement (2 mg estradiol/day, orally for 90 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 23
Study: 11940322

Group type: EXPERIMENTAL
Intervention: Primary intracoronary stenting
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intravenous rt-PA therapy plus rescue intracoronary stenting
Number of subjects: 98
Study: 9804012

Group type: EXPERIMENTAL
Intervention: Dynamic CT with intravenous administration of 40 ml Ioversol (5 cc/s)
Number of subjects: 19
Study: 8904479

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for 'silent' PDA
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Infants with 'silent' PDA
Number of subjects: 290

Group type: COMPARATOR
Intervention: Infants without PDA
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Preterm infants with 'silent' PDA unresponsive to indomethacin
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Preterm infants with 'silent' PDA responsive to indomethacin
Number of subjects: 290
Study: 2797925

Group type: EXPERIMENTAL
Intervention: Formoterol (one puff, 12 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salbutamol (one puff, 100 micrograms)
Number of subjects: 15
Study: 203832

Group type: EXPERIMENTAL
Intervention: Clofibrate and m-Inositolnicotinate (1.5 g Clofibrate and 1.2 g m-Inositolnicotinate daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clofibrate or clofibrinic acid (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (Clofibrate with m-Inositolnicotinate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofibrate with nicotinic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pure nicotinic acid (3 to 4 g/daily) or its esters (4 to 6 g/daily) or beta-Pyridylcarbinol (800 to 1200 mg/daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dosage of nicotinic acid
Number of subjects: 0
Study: 30553401

Group type: EXPERIMENTAL
Intervention: O3-I (omega-3 index) mean 3.7±1.0%
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: O3-I (omega-3 index)
Number of subjects: 899
Study: 26216919

Group type: EXPERIMENTAL
Intervention: Choice-based reality therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not attending the program)
Number of subjects: 44
Study: 25880805

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg od
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 23674107

Group type: EXPERIMENTAL
Intervention: Nebulized isotonic saline (3 mL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nebulized water (3 mL)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Laryngeal desiccation challenge (breathing dry air <1% relative humidity)
Number of subjects: 11
Study: 22263338

Group type: EXPERIMENTAL
Intervention: Delmopinol rinse for 15 seconds
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Delmopinol rinse for 30 seconds
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Delmopinol rinse for 60 seconds
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 4
Study: 19695391

Group type: EXPERIMENTAL
Intervention: 100 mg orally dispersible tablet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 300 mg orally dispersible tablet
Number of subjects: 76

Group type: COMPARATOR
Intervention: Reference 100 mg capsule
Number of subjects: 76
Study: 17041858

Group type: EXPERIMENTAL
Intervention: 16-week structured treatment interruption (STI) followed by optimized ART
Number of subjects: 41

Group type: COMPARATOR
Intervention: Immediate optimized ART (no STI)
Number of subjects: 41
Study: 15658909

Group type: EXPERIMENTAL
Intervention: Mersilene tape
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard metal wire
Number of subjects: 64
Study: 10654902

Group type: EXPERIMENTAL
Intervention: Low-dose estrogen patch (0.05 mg applied twice weekly for 4 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose estrogen patch (0.10 mg applied twice weekly for 4 weeks)
Number of subjects: 12
Study: 10168194

Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Day care
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Domiciliary care after one week of day care
Number of subjects: 437
Study: 8375373

Group type: EXPERIMENTAL
Intervention: 0.2 g lecithin.kg body mass-1 before exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo before exercise
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.2 g lecithin.kg body mass-1 without exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: No lecithin supply during running
Number of subjects: 23